

## ARTICLE

# Heading For An M&A? Understand The Risks And Mitigation Strategies For Clinical Trial Agreements

Published by *Clinical Leader*

November 11, 2025

Changes in ownership in the clinical trial ecosystem can facilitate product pipeline advancement, expand geographic reach, and create operating efficiencies. These transactions also require precise navigation of significant contractual, regulatory, and operational risks. Clinical trial agreements (CTAs) sit at the center of that complexity. Failure to properly review and navigate CTAs during the transaction process can stall closing, trigger regulatory scrutiny, or disrupt ongoing studies.

This article distills key considerations to help anticipate and mitigate the risks that CTAs and diligence in the clinical trial space present during mergers and acquisitions (M&As).

[“Heading For An M&A? Understand The Risks And Mitigation Strategies For Clinical Trial Agreements,”](#) *Clinical Leader*, November 10, 2025

---

## CONTACTS

For more information, contact your Katten attorney or any of the following attorneys.



**Kate Hardey**

+1.704.444.2055

[kate.hardey@katten.com](mailto:kate.hardey@katten.com)

Attorney advertising. Published as a source of information only. The material contained herein is not to be construed as legal advice or opinion.

©2026 Katten Muchin Rosenman LLP.

All rights reserved. Katten refers to Katten Muchin Rosenman LLP and the affiliated partnership as explained at [katten.com/disclaimer](https://www.katten.com/disclaimer).